Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes

Endocrinology and Metabolism Clinics of North America · Published 2026-06-11 · DOI 10.1016/j.ecl.2026.04.015

Authors (2)

Michael S. Hughes, Francisco J. Pasquel

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Hughes, M., Pasquel, F. (2026). Sodium-Glucose Cotransporter-Inhibitors, Incretin Receptor Agonists (Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists), and Finerenone for Kidney Protection in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. https://doi.org/10.1016/j.ecl.2026.04.015

Related articles